BioWorld - Friday, January 17, 2020

Deals and M&A
%{topic} RSS Feed RSS

divest-sell-pie.png

Hologic to sell off 'underperforming' Cynosure, will focus on tuck-ins

November 20, 2019
By Liz Hollis
No Comments
Roughly two and half years after it picked up Cynosure, Hologic Inc., of Marlborough, Mass., has reported its intention to sell it to private equity firm Clayton, Dubilier & Rice (CD&R) for a total purchase price of $205 million in cash, subject to certain closing adjustments. The company expects net cash proceeds of about $138 million. CD&R Partner Derek Strum expressed enthusiasm about the deal, noting that his firm expects “to continue to invest behind the company's strong brand and large global installed base to accelerate growth via expanded sales & marketing efforts and bring new products and technologies to market[.]”
Read More

Ph Pharma and Immunome to collaborate in antibody-drug conjugates

November 20, 2019
By Jihyun Kim
No Comments
HONG KONG - South Korean biopharmaceutical company Ph Pharma Co. Ltd., based in Seoul, and U.S. biotech Immunome Inc., of Exton, Pa., are working together on antibody-drug conjugates (ADCs) in a partnership agreement under which Immunome will discover antibodies using its platform while Ph Pharma will develop the ADC candidates and verify safety and efficacy.
Read More
Deal-puzzle-pieces

BMS redress? Promedior's data corps charms Roche; up to $1.39B payout in IPF

November 18, 2019
By Randy Osborne
No Comments
Any worries by Promedior Inc. investors after Bristol-Myers Squibb Co. (BMS) backed away last year from its option to acquire the firm were resolved in a big way by last week's news that Roche Holding AG is taking over the company in a transaction valued as high as $1.39 billion. Privately held, Lexington, Mass.-based Promedior's lead asset is PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that won breakthrough designation from the FDA earlier this year for idiopathic pulmonary fibrosis (IPF).
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe